Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

21.08.13	Healthy Outlook for Healthcare Supported by Trial Milestones, Approvals, Partnerships, and Commercialization - Research Report on Lilly, Celgene, Onyx, Amgen, and GSK (PR Newswire)
20.08.13	Financial Results and Clinical Study Outcomes - Research Report on Agilent, Perrigo, Lilly, Novavax, and Raptor Pharmaceutical (PR Newswire)
15.08.13	Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control (PR Newswire)
14.08.13	Critical Alerts For Facebook, Orbitz, Eli Lilly, Dominion Resources, and Endo Pharmaceuticals Released By InvestorsObserver (PR Newswire)
13.08.13	Eli Lilly Lung Cancer Drug Meets Goal Of Increased Survival In Late-stage Study (RTTNews)
13.08.13	Lilly Says Last Stage Necitumumab Study Meets Primary Goal Of Overall Survival (RTTNews)
13.08.13	Lilly Announces Phase III Necitumumab Study Meets Primary Endpoint of Overall Survival (PR Newswire)
12.08.13	Early Briefing and Review: Bristol-Myers Squibb Co., Eli Lilly & Co., Allergan Inc., and Endo Health Solutions Inc. (PR Newswire)
06.08.13	Positive Opinions, Solid Margins, Agreements, and Clinical Trials to Boost Run Rate of Drug Manufacturers - Research Report on Johnson & Johnson, Pfizer, Merck, Bristol-Myers Squibb, and Lilly (PR Newswire)
01.08.13	Lilly, Roswell Park Cancer Institute Partner to Train Minority Clinical Trial Investigators (PR Newswire)
01.08.13	M&As, Strong Earnings, and Share Repurchase Programs Support Optimism for Healthcare - Research Report on Perrigo, Intuitive Surgical, Biogen Idec, Celgene, and Lilly (PR Newswire)
24.07.13	Pre-market Movers For July 24 (AAPL, BA, LLY, DELL, F, PEP, MFB, VMW, CAT, BRCM) (RTTNews)
24.07.13	Lilly Q2 Profit Rises, Above Estimates; Lifts Forecast (RTTNews)
24.07.13	Lilly Q2 Profit Climbs; Ups 2013 Earnings View - Quick Facts (RTTNews)
24.07.13	Lilly Reports Second-Quarter 2013 Results (PR Newswire)
24.07.13	Earnings Watch For July 24 (BA, CAT, F, FB, V, CA) (RTTNews)
23.07.13	Transition In-licenses TT-601 From Lilly For Osteoarthritis Pain - Quick Facts (RTTNews)
22.07.13	Successful Integrations, Growth Brands, and Pipeline Innovations Boost Revenue Growth - Research Report on Johnson & Johnson, Abbott, St. Jude Medical, Lilly, and Novartis (PR Newswire)
08.07.13	Eli Lilly, Boehringer Say MAA For LY2963016 Accepted For Review By EMA (RTTNews)
08.07.13	Lilly, Boehringer Report Regulatory Submission For Insulin Glargine Biosimilar (RTTNews)
08.07.13	Eli Lilly CEO Returns To Work After Surgery - Update (RTTNews)
08.07.13	Lilly Chairman John Lechleiter Back To Duty After Dilated Aorta Surgery (RTTNews)
08.07.13	Lilly: CMS Issues Draft Decision Proposing Coverage With Evidence Development (RTTNews)
08.06.09	Wall Street Schluss: Später Aufwind, Finanztitel legen zu (Aktiencheck)
06.11.08	Cabernet Pharmaceuticals and Lilly Form Pharmacogenetics Alliance to Help Deliver Tailored Therapeutics to Patients (Businesswire)
11.06.08	NOXXON Pharma AG schliesst Kooperationsvertrag mit Eli Lilly and Company über die Entwicklung von Spiegelmeren(R) zur Migränebehandlung (Businesswire)
21.05.08	Lilly Announces Changes in Key Leadership Roles (PR Newswire)
09.05.08	Seven Summits Research Releases Comments on XOM, NVDA, ICE, LLY, and ATVI (PR Newswire)
30.04.08	Lilly CEO Praises Massachusetts' Leadership in Biotech, Urges Policy Prescriptions to Help Ensure State's Investment Generates Dividends and Jobs (PR Newswire)
11.04.08	ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer (PR Newswire)
05.03.08	AOL, Lilly and VeriSign Return as Sponsors & NSA Returns as Patron of 2008 TopCoder Open (PR Newswire)
15.11.07	Eli Lilly and Company to Receive Honor from National Urban League (PR Newswire)
06.11.07	Lilly Contributes $10.8 Million to United Way Annual Campaign (PR Newswire)
01.10.07	Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize (PR Newswire)
21.09.07	One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function (PR Newswire)
21.09.07	One Year of Exenatide Treatment Improves Beta-Cell Function (PR Newswire)
19.09.07	EASD/EFSD, Chinese Diabetes Society and Eli Lilly and Company partner to support collaborative diabetes research between China and Europe (PR Newswire)
18.09.07	European Study Outlines Struggle to Control Diabetes, Significant Economic Implications to Healthcare Systems (PR Newswire)
11.07.07	European Commission Approves FORSTEO(R) (teriparatide [rDNA origin] injection) for the Treatment of Osteoporosis in Men (PR Newswire)
02.06.07	Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer (PR Newswire)
19.02.07	Eli Lilly and Company Aligns with Veterinary Channel Partners (PR Newswire)
19.02.07	Eli Lilly and Company Aligns with Veterinary Channel Partners (Businesswire)
12.02.07	Scholarship Recognizes Adults With Attention-Deficit/Hyperactivity Disorder Striving for Academic Excellence (PR Newswire)
18.01.07	Lilly ICOS LLC Reports Results for 2006 (PR Newswire)
12.01.07	Glass Lewis and PROXY Governance Recommend ICOS Shareholders Vote for Lilly's $34 Per Share Cash Merger (Businesswire)
11.01.07	Lilly Announces Strategic Changes to its Global Manufacturing Operations (PR Newswire)
05.01.07	Lilly and OSI Pharmaceuticals Announce Licensing Agreement (PR Newswire)
17.12.06	Eli Lilly and Company Responds to New York Times Article of 12/17/06 (PR Newswire)
21.11.06	BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission (PR Newswire)
28.09.06	2006 Lilly Oncology On Canvas(SM) International Art Competition Receives More Than 2,000 Entries (PR Newswire)
21.07.06	Lilly Reports Second-Quarter EPS of $.76 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

06:09		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
27.12.24		SLI-Handel aktuell: Zum Handelsende Gewinne im SLI
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester
27.12.24		Börse Frankfurt: DAX zum Handelsende auf grünem Terrain
27.12.24		Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge

06:09

Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen

27.12.24

Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus

27.12.24

BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester

27.12.24

Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

27.12.24

SLI-Handel aktuell: Zum Handelsende Gewinne im SLI

27.12.24

Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester

27.12.24

Börse Frankfurt: DAX zum Handelsende auf grünem Terrain

27.12.24

Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten